Literature DB >> 16741062

Endothelin-1 is required during epithelial to mesenchymal transition in ovarian cancer progression.

Laura Rosanò1, Francesca Spinella, Valeriana Di Castro, Samantha Decandia, Maria Rita Nicotra, Pier Giorgio Natali, Anna Bagnato.   

Abstract

In a range of human cancers, tumorigenesis is promoted by activation of the endothelin A receptor (ET(A)R)/endothelin-1 (ET-1) axis. ET-1 and ET(A)R are overexpressed in primary and metastatic ovarian carcinomas, and high levels of ET-1 are detectable in patient ascites, suggesting that ET-1 may promote tumor dissemination. Moreover, in these tumors, engagement of ET(A) receptor by ET-1 triggers tumor growth, survival, angiogenesis, and invasiveness. Thus, ET-1 enhances the secretion of matrix metalloproteinases, disrupts intercellular communications, and stimulates cell migration and invasion. Therefore, we investigated the role of the ET-1/ET(A)R autocrine axis in promoting epithelial to mesenchymal transition (EMT) in ovarian tumor cells, a key event in cancer metastasis, in which epithelial cells depolarize, disassemble cell-cell contacts, and adopt an invasive phenotype. Here, we examine the potential role of ET-1 in regulating cell morphology and behavior and epithelial and mesenchymal proteins employing an in vitro 3-D culture system. We found that in 3-D serum-free collagen I gel cultures, HEY and OVCA 433 ovarian carcinoma cells undergo fibroblast-like morphologic changes between 3 and 5 days of ET-1 treatment. In these cells, ET-1 induces loss of adherens and tight-junction protein expression, E-cadherin, beta-catenin, and zonula occludens-1, and gain of N-cadherin and vimentin expression. These results confirm the ability of ET-1 to promote EMT, a metastable process involving sustained loss of epithelial markers and gain of mesenchymal markers. Collectively, these findings provide evidence of a critical role for the ET-1/ET(A)R axis during distinct steps of ovarian carcinoma progression, thus underlining this axis as a potential target in the treatment of ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16741062

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  12 in total

1.  Phase 1/2 study of atrasentan combined with pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer.

Authors:  Petronella O Witteveen; Koen J C van der Mijn; Maartje Los; Roelien H Kronemeijer; Gerard Groenewegen; Emile E Voest
Journal:  Neoplasia       Date:  2010-11       Impact factor: 5.715

2.  C3G overexpression in glomerular epithelial cells during anti-GBM-induced glomerulonephritis.

Authors:  Victoriya A Rufanova; Elias Lianos; Anna Alexanian; Elena Sorokina; Mukut Sharma; Ann McGinty; Andrey Sorokin
Journal:  Kidney Int       Date:  2008-09-10       Impact factor: 10.612

Review 3.  Activated epidermal growth factor receptor in ovarian cancer.

Authors:  Laurie G Hudson; Reema Zeineldin; Melina Silberberg; M Sharon Stack
Journal:  Cancer Treat Res       Date:  2009

4.  Applicability of green fluorescence protein in the study of endothelin converting enzyme-1c trafficking.

Authors:  Sanjaya Kuruppu; Nathalie Tochon-Danguy; A Ian Smith
Journal:  Protein Sci       Date:  2013-02-01       Impact factor: 6.725

5.  Three-dimensional in vitro cell biology models of ovarian and endometrial cancer.

Authors:  B Grun; E Benjamin; J Sinclair; J F Timms; I J Jacobs; S A Gayther; D Dafou
Journal:  Cell Prolif       Date:  2009-02-16       Impact factor: 6.831

6.  An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ.

Authors:  Martin Götte; Christian Kersting; Isabel Radke; Ludwig Kiesel; Pia Wülfing
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

7.  Loss expression of micro ribonucleic acid (miRNA)-200c induces adverse post-surgical prognosis of advanced stage non-small cell lung carcinoma and its potential relationship with ETAR messenger RNA.

Authors:  Jinpeng Zhao; Yandong Zhao; Zizong Wang; Yunpeng Xuan; Yiren Luo; Wenjie Jiao
Journal:  Thorac Cancer       Date:  2015-07-02       Impact factor: 3.500

8.  [Expression and clinical relevance of uPA and ET-1 in non-small cell lung cancer].

Authors:  Yanyi Jiang; Yizhen Liu; Zhizhou Shi; Boshi Wang; Li Shang; Xin Xu; Shengzhou Zhang; Mingrong Wang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2011-01

9.  Correlations between plasma endothelin-1 levels and breakthrough pain in patients with cancer.

Authors:  Xue-Bin Yan; Tuo-Chao Peng; Dong Huang
Journal:  Onco Targets Ther       Date:  2015-12-08       Impact factor: 4.147

10.  Upregulation of Endothelin-1/Endothelin A Receptor Expression Correlates with Heparanase Expression in Ovarian Carcinoma.

Authors:  Nungki Anggorowati; Ahmad Ghozali; Irianiwati Widodo; Dwi Cahyani Ratna Sari; Muhammad Mansyur Romi; Nur Arfian
Journal:  Iran J Med Sci       Date:  2018-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.